论文部分内容阅读
目的探讨甲状腺乳头状癌中CD44v6、BRAF和Rasp21的表达,及其与淋巴结转移的关系。方法应用免疫组化SP法,对38例有颈淋巴结转移的甲状腺乳头状癌(PTC+LNM)患者、22例甲状腺乳头状癌但无颈部淋巴结转移患者和50例甲状腺腺瘤(TA)患者组织中的CD44v6、BRAF和Rasp21进行检测。结果有淋巴结转移组(PTC+LNM)的CD44v6、BRAF和Rasp21阳性率显著高于无淋巴结转移组(PTC)和甲状腺腺瘤(TA)组(P<0.05)。结论 CD44v6、BRAF和Rasp21的阳性表达与甲状腺乳头状癌的颈淋巴结转移密切相关,可作为甲状腺乳头状癌较好的转移及预后评估指标。
Objective To investigate the expression of CD44v6, BRAF and Rasp21 in papillary thyroid carcinoma and their relationship with lymph node metastasis. Methods Thirty-eight patients with thyroid papillary carcinoma (PTC + LNM) with cervical lymph node metastasis, 22 patients with papillary thyroid carcinoma without cervical lymph node metastasis and 50 patients with thyroid adenoma (TA) were studied by immunohistochemical SP method. Tissues CD44v6, BRAF and Rasp21 were tested. Results The positive rates of CD44v6, BRAF and Rasp21 in patients with lymph node metastasis (PTC + LNM) were significantly higher than those without lymph node metastasis (PTC) and thyroid adenoma (TA) (P <0.05). Conclusion The positive expression of CD44v6, BRAF and Rasp21 are closely related to the cervical lymph node metastasis of papillary thyroid carcinoma, which can be used as a good indicator of metastasis and prognosis of papillary thyroid carcinoma.